Medical Cannabis Studies

• View All (505)

Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. (2019)

Pharmacological research on compounds derived from Cannabis sativa has never ended. The purpose of this review was to clarify the pharmacological activity of cannabidiol (CBD) and its multiple therapeutic applications. In addition, the critical and conflicting results of the research on the (CBD) are discussed with a focus on promising future prospects. View study
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation (2012)

In this study, a comparison between CBDA and cannabidiol, CBDA showed a markedly higher potency to inhibit vomiting in animal models. As a result, CBDA has great potential in the treatment of nausea, vomiting and anticipatory nausea for which there is currently no therapy. View study
Cannabidivarin is anticonvulsant in mouse and rat (2012)

The anticonvulsant profile of cannabidivarin CBDV is investigated for the first time in invitro and in vivo models, demonstrating that it is an effective anticonvulsant without significantly affecting normal motor function. View study
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism (2013)

Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study
Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines [Internet] (2016)

The objective of this research is to review the available published literature related to the oral spray THC: CBD for the treatment of chronic neuropathic or neuropathic pain in adults. Studies have been conducted on the therapeutic use of various synthetic cannabinoid products for the symptomatic relief of chronic pain. View study
Cannabinoid CB1 receptor binding and acetylcholinesterase inhibitory activity of Sceletium tortuosum L. (2010)

In this study it was found that the unfermented alkaloid extract possesses a higher activity to bind to the CB1 receptor compared to the fermented one. The GC-MS analysis confirmed that the non-fermented alcoloid extract contains more alkaloids than the fermented one. View study
Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence (2014)

In the present study we want to verify if interfering directly with the metabolism and reuptake of the endocannabinoids (BCE), in the pre-limbic (PL) portion of the medial prefrontal cortex (PFC) (MPFC) and dorsal HIP (dHIP) would produce different effects in Two conceptually different animal models: the highest labyrinth (EPM) and the Vogel conflict test (VCT). View study
Cannabinoid CB2 receptors in human brain inflammation (2008)

The anti-inflammatory effects triggered by the activation of CB2 receptor make it an attractive target for the development of new anti-inflammatory therapies. In any case, more research is needed to corroborate the potential utility of cannabinoid-based treatments devoid of unwanted psychoactive effects View study
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation (2008)

CB2 cannabinoid receptors constitute a physiopathological mechanism for the resolution of inflammation in gastrointestinal disorders, thus being a very promising therapeutic objective. View study
Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint (2013)

This study shows that cannabinoid receptors 2 (CB2) inhibit and contribute to pain relief from the prevalent joint disease, called osteoarthritis (OA). The data provided by this study provide new clinically relevant evidence that joint damage and spinal CB2 receptor expression are correlated in combination with convergent preclinical evidence that activation of CB2 receptors inhibits central sensitization and its contribution to the manifestation of chronic pain of the (OA). View study
Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor (2014)

There is convergent anatomical and biochemical evidence that functional CB1 receptors are found in the mitochondria of the brain at low levels. With these data it is possible to conclude that there may be a direct relationship between the CB1 receptor and the mitochondrial functions in the brain and can be detected if certain experimental procedures are applied. View study
Cannabinoid Delivery Systems for Pain and Inflammation Treatment. (2018)

This review aimed to explore the most recent developments, from preclinical to advanced clinical trials, in the field of cannabinoid administration, and focuses particularly on the treatment of pain and inflammation. Future probable directions are also considered and reported. View study